yap1 inhibitor verteporfin Search Results


verteporfin  (MedChemExpress)
98
MedChemExpress verteporfin
( A,B ) Detected by Western blotting, the protein expression of <t>YAP1,</t> P-YAP, TEAD1, and TEAD4 in HUVECs treated with <t>Verteporfin</t> (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( C ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( D ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( E,F ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (40×). ( G,H ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( I ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7(1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. ( J ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h simultaneously intervened with Verteporfin (1 μM) for 48 h. ( K,L ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. Scale bars: 50 μm (40×). Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (B,C,D,F,H,I,J,L)]. CTRL, Control group. * represents the significance of Treat versus NC in the Control mouse model, and # represents the significance of Treat versus NC in the LPS-treated mouse model. #P<0.05
Verteporfin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/yap1+inhibitor+verteporfin/Verteporfin/pmc11196208-17-0-4
Average 98 stars, based on 1 article reviews
verteporfin - by Bioz Stars, 2026-08
98/100 stars
  Buy from Supplier
verteporfin  (Selleck Chemicals)
95
Selleck Chemicals verteporfin
( A,B ) Detected by Western blotting, the protein expression of <t>YAP1,</t> P-YAP, TEAD1, and TEAD4 in HUVECs treated with <t>Verteporfin</t> (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( C ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( D ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( E,F ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (40×). ( G,H ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( I ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7(1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. ( J ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h simultaneously intervened with Verteporfin (1 μM) for 48 h. ( K,L ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. Scale bars: 50 μm (40×). Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (B,C,D,F,H,I,J,L)]. CTRL, Control group. * represents the significance of Treat versus NC in the Control mouse model, and # represents the significance of Treat versus NC in the LPS-treated mouse model. #P<0.05
Verteporfin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/yap1+inhibitor+verteporfin/Verteporfin/pmc12374829-32-45-50
Average 95 stars, based on 1 article reviews
verteporfin - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
yap1 inhibitor cat no 5305  (Tocris)
95
Tocris yap1 inhibitor cat no 5305
( A,B ) Detected by Western blotting, the protein expression of <t>YAP1,</t> P-YAP, TEAD1, and TEAD4 in HUVECs treated with <t>Verteporfin</t> (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( C ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( D ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( E,F ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (40×). ( G,H ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( I ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7(1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. ( J ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h simultaneously intervened with Verteporfin (1 μM) for 48 h. ( K,L ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. Scale bars: 50 μm (40×). Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (B,C,D,F,H,I,J,L)]. CTRL, Control group. * represents the significance of Treat versus NC in the Control mouse model, and # represents the significance of Treat versus NC in the LPS-treated mouse model. #P<0.05
Yap1 Inhibitor Cat No 5305, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/yap1+inhibitor+verteporfin/Verteporfin/pm38943285-59-23-28
Average 95 stars, based on 1 article reviews
yap1 inhibitor cat no 5305 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


( A,B ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with Verteporfin (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( C ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( D ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( E,F ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (40×). ( G,H ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( I ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7(1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. ( J ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h simultaneously intervened with Verteporfin (1 μM) for 48 h. ( K,L ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. Scale bars: 50 μm (40×). Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (B,C,D,F,H,I,J,L)]. CTRL, Control group. * represents the significance of Treat versus NC in the Control mouse model, and # represents the significance of Treat versus NC in the LPS-treated mouse model. #P<0.05

Journal: Clinical Science (London, England : 1979)

Article Title: IGFBP7 promotes endothelial cell repair in the recovery phase of acute lung injury

doi: 10.1042/CS20240179

Figure Lengend Snippet: ( A,B ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with Verteporfin (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( C ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( D ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( E,F ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with Verteporfin (1 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (40×). ( G,H ) Detected by Western blotting, the protein expression of YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( I ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7(1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. ( J ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h simultaneously intervened with Verteporfin (1 μM) for 48 h. ( K,L ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h. Scale bars: 50 μm (40×). Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (B,C,D,F,H,I,J,L)]. CTRL, Control group. * represents the significance of Treat versus NC in the Control mouse model, and # represents the significance of Treat versus NC in the LPS-treated mouse model. #P<0.05".Please add " ##P<0.01.

Article Snippet: Verteporfin (YAP1 inhibitor) , MCE , Cat# HY-B0146.

Techniques: Western Blot, Expressing, Control, Quantitative RT-PCR, CCK-8 Assay, Staining

( A,B ) String and Genemania databases were used to predict the potential regulatory molecules of IGFBP7. ( C,D ) Detected by Western blotting, the protein expression of c-FOS in HUVECs intervened with rhIGFBP7 (0, 200, 500, 1000, and 2000 ng/ml) for 48 h, internal control for normalization: β-Actin. ( E,F ) Detected by Western blotting, the protein expression of c-FOS in HUVECs transfected with IGFBP7 siRNA for 48 h and treated with LPS (5 µg/ml) for 24 h, internal control for normalization: β-Actin. ( G,H ) Representative images of c-FOS-AF555 and DAPI co-staining in HUVECs transfected with IGFBP7 siRNA for 48 h. Scale bars: 50 μm (40×). ( I,J ) Representative images of c-FOS-AF555 and DAPI co-staining in HUVECs intervened with rhIGFBP7 (1 μg/ml) for 48 h. Scale bars: 50 μm (40×). ( K–L ) Detected by Western blotting, the protein expression of c-FOS in HUVECs treated with Verteporfin (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( M,N ) Detected by Western blotting, the protein expression of c-FOS in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( O,P ) Detected by Western blotting, the protein expression of C-FOS, YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with T5224 (40 μM, a C-FOS inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( Q,R ) Detected by Western blotting, the protein expression of C-FOS, YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with T5224 (40 μM, a C-FOS inhibitor) for 48 h, internal control for normalization: β-Actin. ( S,T ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (20×). ( U ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( V ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( W,X ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. Scale bars: 50 μm (40×). ( Y ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. ( Z ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (D,F,L,N,P,R,T,U,V,X,Y,Z)] and t -test (H,J). CTRL, Control group.

Journal: Clinical Science (London, England : 1979)

Article Title: IGFBP7 promotes endothelial cell repair in the recovery phase of acute lung injury

doi: 10.1042/CS20240179

Figure Lengend Snippet: ( A,B ) String and Genemania databases were used to predict the potential regulatory molecules of IGFBP7. ( C,D ) Detected by Western blotting, the protein expression of c-FOS in HUVECs intervened with rhIGFBP7 (0, 200, 500, 1000, and 2000 ng/ml) for 48 h, internal control for normalization: β-Actin. ( E,F ) Detected by Western blotting, the protein expression of c-FOS in HUVECs transfected with IGFBP7 siRNA for 48 h and treated with LPS (5 µg/ml) for 24 h, internal control for normalization: β-Actin. ( G,H ) Representative images of c-FOS-AF555 and DAPI co-staining in HUVECs transfected with IGFBP7 siRNA for 48 h. Scale bars: 50 μm (40×). ( I,J ) Representative images of c-FOS-AF555 and DAPI co-staining in HUVECs intervened with rhIGFBP7 (1 μg/ml) for 48 h. Scale bars: 50 μm (40×). ( K–L ) Detected by Western blotting, the protein expression of c-FOS in HUVECs treated with Verteporfin (1 μM, a YAP1 inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( M,N ) Detected by Western blotting, the protein expression of c-FOS in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with Verteporfin (1 μM) for 48 h, internal control for normalization: β-Actin. ( O,P ) Detected by Western blotting, the protein expression of C-FOS, YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with T5224 (40 μM, a C-FOS inhibitor) for 48 h, simultaneously with a 24 h LPS treatment, internal control for normalization: β-Actin. ( Q,R ) Detected by Western blotting, the protein expression of C-FOS, YAP1, P-YAP, TEAD1, and TEAD4 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h, simultaneously intervened with T5224 (40 μM, a C-FOS inhibitor) for 48 h, internal control for normalization: β-Actin. ( S,T ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. Scale bars: 50 μm (20×). ( U ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( V ) Determined by the CCK-8 assay, the cell viability of HUVECs intervened with T5224 (40 μM) for 48 h, concurrently treated with LPS (5 μg/ml) for 24 h. ( W,X ) Representative images of EDU-AF488 and DAPI co-staining in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. Scale bars: 50 μm (40×). ( Y ) Assessed by qRT-PCR, the mRNA expression of CCNB1, CCNC, CCND1, CCNE1, SOX17, EGFR, and KI67 in HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. ( Z ) Determined by the CCK-8 assay, the cell viability of HUVECs treated with rhIGFBP7 (1 μg/ml) for 48 h and simultaneously intervened with T5224 (40 μM) for 48 h. Data represented as means ± SDs. * P <0.05, ** P <0.01, *** P <0.005,**** P <0.001 [one-way ANOVA, Tukey’s test (D,F,L,N,P,R,T,U,V,X,Y,Z)] and t -test (H,J). CTRL, Control group.

Article Snippet: Verteporfin (YAP1 inhibitor) , MCE , Cat# HY-B0146.

Techniques: Western Blot, Expressing, Control, Transfection, Staining, Quantitative RT-PCR, CCK-8 Assay

Journal: Clinical Science (London, England : 1979)

Article Title: IGFBP7 promotes endothelial cell repair in the recovery phase of acute lung injury

doi: 10.1042/CS20240179

Figure Lengend Snippet:

Article Snippet: Verteporfin (YAP1 inhibitor) , MCE , Cat# HY-B0146.

Techniques: Ubiquitin Proteomics, Recombinant, SYBR Green Assay, CCK-8 Assay, Extraction, Proliferation Assay, Immunoprecipitation